a bit late in responding, but thanks comincon for explaining in plain english what the consumer market has virtually no understanding of - that being, despite the government making CBD legal over the counter since early this year, the S3 pursuit is a difficult pathway for any company and really only has benefit for Australian sales. First to market may be a big beneficiary, but the label claim is the big impediment - that rrquires clinical research which takes time and money. I'm glad IHL has opted to drop its oils and focus on global pharmaceutical unmet indications.
- Forums
- ASX - By Stock
- General discussion
a bit late in responding, but thanks comincon for explaining in...
-
- There are more pages in this discussion • 11,165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some